Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Submitted by
admin
on October 3, 2018 - 9:33am
Source:
CP Wire
News Tags:
Genentech/Roche
risdiplam
spinal muscular atrophy
Headline:
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
snippet:
During 8 month visit 57% of infants showed improvement during time when most with Type 1 SMA show no improvement or decline
Risdiplam is delivered orally
Risdiplam is being co-developed with PTC Therapeutics
Do Not Allow Advertisers to Use My Personal information
